

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.                            | FILING DATE     | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |  |
|--|-----------------|----------------------|-------------------------|------------------|--|
| 09/582,734                                 | 10/06/2000      | Ib Mendel-Hartvig    | 10806-129               | 1611             |  |
| 24256                                      | 7590 11/18/2002 |                      |                         |                  |  |
|  | & SHOHL, LLP    | EXAMINER             |                         |                  |  |
| 1900 CHEME                                 |                 | COUNTS, GARY W       |                         |                  |  |
| 255 EAST FIFTH STREET CINCINNATI, OH 45202 |                 |                      |                         |                  |  |
| Chreman                                    | , 011 43202     |                      | ART UNIT                | PAPER NUMBER     |  |
|  |                 |                      | 1641                    | •                |  |
|  |                 |                      | DATE MAILED: 11/18/2002 | <b>{</b> }       |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|   |  | Application No.  |   | Applicant(s)  |  |  |  |
|---|--|--|---|---|--|--|--|
|   | •  | 09/582,734   |   | MENDEL-HARTVIG ET AL.   |  |  |  |
|   | Office Action Summary  | Examiner   |   | Art Unit  |  |  |  |
|   |  | Gary W. Counts   |   | 1641  |  |  |  |
| Period fo   | Th MAILING DATE of this communication apor Reply   |  |   | rrespondence address  |  |  |  |
| THE - Exte after - If the - If NO - Failu - Any   | ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. Propriod for reply specified above is less than thirty (30) days, a reploperiod for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statutively received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b). | 136(a). In no event, howed<br>by within the statutory min<br>will apply and will expire<br>e, cause the application to | ever, may a reply be time<br>nimum of thirty (30) days v<br>SIX (6) MONTHS from the<br>b become ABANDONED | by filed  will be considered timely. e mailing date of this communication. (35 U.S.C. § 133). |  |  |  |
| 1)⊠   | Responsive to communication(s) filed on 04   | September 2002   |   |   |  |  |  |
| 2a)⊠  | This action is <b>FINAL</b> . 2b) ☐ TI   | his action is non-fi   | nal.  |   |  |  |  |
| 3)□<br>Dispositi  | Since this application is in condition for allow closed in accordance with the practice under ion of Claims  | rance except for for for Ex parte Quayle,  | ormal matters, pro<br>1935 C.D. 11, 45  | secution as to the merits is 3 O.G. 213.  |  |  |  |
| 4)⊠   | Claim(s) 1-4 and 6-33 is/are pending in the a  | pplication.  | •   |   |  |  |  |
|   | 4a) Of the above claim(s) is/are withdrawn from consideration.   |  |   |   |  |  |  |
| 5)  | Claim(s) is/are allowed.   |  |   |   |  |  |  |
| 6)⊠   | Claim(s) 1-4 and 6-33 is/are rejected.   |  | •   |   |  |  |  |
| 7)  | Claim(s) is/are objected to.   |  |   |   |  |  |  |
| 8) Claim(s) are subject to restriction and/or election requirement.   |  |  |   |   |  |  |  |
| Applicati   | on Papers  |  |   |   |  |  |  |
| 9) 🗌 .  | The specification is objected to by the Examine  | er.  |   |   |  |  |  |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  |  |  |   |   |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).   |  |  |   |   |  |  |  |
| 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.   |  |  |   |   |  |  |  |
| If approved, corrected drawings are required in reply to this Office action.  |  |  |   |   |  |  |  |
|   | The oath or declaration is objected to by the Ex   | kaminer.   |   |   |  |  |  |
| Priority u  | inder 35 U.S.C. §§ 119 and 120   |  |   |   |  |  |  |
| 13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  |  |  |   |   |  |  |  |
| a)⊠ All b)□ Some * c)□ None of:   |  |  |   |   |  |  |  |
|   | 1. Certified copies of the priority document   | ts have been rece  | ived.   |   |  |  |  |
|   | 2. Certified copies of the priority document   | ts have been rece  | ived in Applicatior   | 1 No  |  |  |  |
| <ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul> |  |  |   |   |  |  |  |
|   | cknowledgment is made of a claim for domest  |  | •   |   |  |  |  |
| a)  | ☐ The translation of the foreign language proceeds. The translation of the foreign language proceeds. The composition of the foreign language proceeds.  | ovisional application  | on has been recei   | ved.  |  |  |  |
| Attachment  |  |  |   |   |  |  |  |
| 2) Notice 3) Inform   | e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) 1  | 4)   |   | PTO-413) Paper No(s) tent Application (PTO-152)   |  |  |  |
| S. Patent and Tre<br>TO-326 (Rev  |  | ction Summary  |   | Part of Paper No. 14  |  |  |  |

Application/Control Number: 09/582,734

Art Unit: 1641

#### **DETAILED ACTION**

### Status of the claims

The amendment filed September 4, 2002 is acknowledged and has been entered.

## Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 12, and 18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 12, line 3 "...." is vague. It is unclear what applicant intends and it is also unclear what these "....'s) represent.

Claim 18 part (e) "adapted" is vague and indefinite. It is unclear what the term encompasses and further, it is unclear how the device is adapted.

## Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 1-4, 6-14, 18-28, 32 and 33 rejected under 35 U.S.C. 102(b) as being anticipated by Dafforn et al (US Patent 4,981,786).

Dafforn et al disclose an immunoassay device and method for determining an analyte in a sample. Dafforn et al also disclose that the device comprises a bibulous

Art Unit: 1641

material which is susceptible to traversal by an aqueous medium in response to capillary force (flow matrix), (col 7, lines 8-10). Dafforn et al disclose that the device may be used in assays wherein absorbent material is utilized to assist the flow of liquid away from a contact portion where the absorbent material is contacted with a medium containing the analyte to be determined or reagents for analyzing for the analyte (col 4, lines10-16). Dafforn et al disclose the device comprises a first means for introducing a sample into the device and second means other than the first means for introducing a liquid reagent other than the sample into the device (col 3, lines1-20). Dafforn et al disclose that the liquid reagent (Reactant\*) is added upstream of the test solution (sample) and that both of these application zones are located upstream of a immunosorbing zone (detection zone) and that specific binding members (antibodies) are immobilized in the immunosorbing zone (col 18, line 3 – col 19, line 48). Dafforn et al also disclose that the sample may be introduced before the liquid reagent if so desired (col 18, lines 20-32). Dafforn et al disclose that the contact portion can also serve as the immunsorbing zone (detection zone) or separate immunosorbing zones can be utilized depending on the particular assay protocol chosen (col 18, lines 45-48). Dafforn et al also disclose that the application of liquid can be performed simultaneously in the application zones (col 24, lines 30-32). Dafforn et al also disclose that the reagents can be predeposited in the matrix. Dafforn et al also disclose packaging the components into a kit.

# Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 15, 16, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dafforn et al in view of Robinson et al (WO 95/16914).

See above for teachings of Dafforn et al.

Dafforn et al differ from the instant invention in failing to disclose the matrix comprising at least one calibrator zone, in which calibrator is bound.

Robinson et al disclose the use of calibration zone(s), in which a calibration reagent is immobilized and has biospecific affinity for the analyte of interest or the binding partner of interest (page 15, lines 15-24). Robinson et al also disclose that the device may be a flow through device such as a lateral flow matrix (page 5, lines 7-22).

Robinson et al also disclose that the specific binding partner can be coupled to or conjugated to the calibrator (see page 17), to form a complex for detection. Robinson et al disclose that the reagents may be antigen/antibody complexes. Robinson et al disclose that calibrator zones used in this manner offers means for calibrating the assay as part of the assay procedure (page 3, lines 15-16) and also provides advantages for additional compensation for various factors in the assay system which may influence the level of signal observed (page 14, lines 24-26).

It would have been obvious to one of ordinary skill in the art to incorporate the use of a calibrator zone as taught by Robinson et al into the method and device of Dafforn et al because Robinson et al disclose that calibrator zones used in this manner offers means for calibrating the assay as part of the assay procedure (page 3, lines 15-16) and also provides advantages for additional compensation for various factors in the assay system which may influence the level of signal observed (page 14, lines 24-26).

3. Claims 17 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dafforn et al (US Patent 4,981,786) in view of Self et al (US Patent 4,446,231).

See above for teachings of Dafforn et al.

Dafforn et al and differ from the instant invention in failing to teach the diagnosis of an autoimmune disease.

Self et al disclose that immunoassays are used for the detection and/or determination of autoimmune diseases. Self et al shows that immunoassays have a wide application, in both clinical and non-clinical fields and that they are particularly useful in any circumstance where it is necessary to detect and/or determine small or very small amounts of substances.

It would have been obvious to one of ordinary skill in the art to use immunoassays as taught by Self et al for the diagnosis of autoimmune diseases because Self et al shows that immunoassays are used for the detection and/or determination of autoimmune diseases and that immunoassays have a wide application, in both clinical and non-clinical fields and that they are particularly useful in any

circumstance where it is necessary to detect and/or determine small or very small amounts of substances. Therefore it would have been obvious to one of ordinary skill in the art to use the device and method of Dafforn et al for diagnosing autoimmune disease.

### Response to Arguments

5. Applicant's arguments filed September 4, 2002 have been fully considered but they are not persuasive.

Applicant argues that the Dafforn et al reference fails to teach or suggest a method or device wherein flow is initiated by adding liquid to each zone in such a way that liquid<sub>n+1</sub> added to the application  $LZ_{n+1}$  contacts the flow matrix substantially simultaneously and is transported through the matrix immediately after liquid, added to the nearest downstream application zone LZ<sub>n</sub>. This is not found persuasive because Dafforn et al disclose that the application of liquid reagent and sample can be added sequentially or simultaneously. One skilled in the art would recognize that if the liquid reagent and sample are applied simultaneously that they would both contact the flow matrix almost simultaneously and since the sample is located downstream of the liquid reagent, the liquid reagent would be transported through the matrix immediately after the sample. Therefore, it is the Examiner's position that the Dafforn et al reference reads on the instant claims.

Applicant argues that the Robinson et al reference does not resolve the deficiencies of the Dafforn et al reference. Applicant states that there is no teaching or Application/Control Number: 09/582,734

Art Unit: 1641

suggestion for employing any of the elements of Robinson et al's sensor device in the multiple port assay device of Dafforn et al and that only in hindsight of the methods and devices of the instant claims would one of ordinary skill in the art have any motivation for combining the teachings of Dafforn et al and Robinson et al along the lines of the present invention. This is no found persuasive because as noted in the previous office action Robinson et al disclose that the calibrator zones offers means for calibrating the assay as port of the assay procedure (page 3, lines 15-16) and also provides advantages for addition al compensation for various factors in the assay system which may influence the level of signal observed. Regarding hindsight, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

Applicant argues that the Self et al reference does not resolve the deficiencies of Dafforn et al, whereby the combination of Dafforn et al and Self et al does not render the method and devices of claims 17 and 31 obvious. This is not found persuasive because Dafforn et al specifically teach that the device may be utilized in any number of assay wherein absorbent material is utilized to assist the flow of liquid away from a contact portion where the absorbent material is contacted with a medium containing the analyte to be determined or reagents for analyzing for the analyte (col 4, lines 11-16). Further,

Dafforn et al disclose that the device can be used to detect autoimmune antibodies and antibodies to allergens (col 5, lines 1-6). Since, Self et al disclose that immunoassays are used for the detection and/or determination of autoimmune disease. It would have been obvious to one of ordinary skill in the art to combine the teachings of Dafforn et al and Self et al.

### Conclusion

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary W. Counts whose telephone number is (703) 305-1444. The examiner can normally be reached on M-F 8:00 - 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (703) 305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703)308-4242 for regular communications and (703)3084242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Lany Counts

Examiner

Art Unit 1641

November 8, 2002

LONG V. LE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

11/24/02